Related references
Note: Only part of the references are listed.Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER plus Advanced Breast Cancer
Ben O'Leary et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti et al.
CLINICAL CANCER RESEARCH (2020)
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui et al.
CLINICAL CANCER RESEARCH (2020)
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao et al.
LANCET ONCOLOGY (2020)
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Seth A. Wander et al.
CANCER DISCOVERY (2020)
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pingping Mao et al.
CLINICAL CANCER RESEARCH (2020)
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models
Sylvia Gruenewald et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
Daniel Morgensztern et al.
LUNG CANCER (2019)
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
Tim H. Holmstrom et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer
Kristina Golfmann et al.
ONCOGENE (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma
Elizabeth C. Smyth et al.
CANCER DISCOVERY (2017)
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models
Federica Guffanti et al.
NEOPLASIA (2017)
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer
Luigi Formisano et al.
CLINICAL CANCER RESEARCH (2017)
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Paul K. Paik et al.
CLINICAL CANCER RESEARCH (2017)
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
A. W. Tolcher et al.
ANNALS OF ONCOLOGY (2016)
NGS-based measurement of gene expression of 2560 oncology-related biomarkers in formalin-fixed, paraffin-embedded (FFPE) tissues
Monica M. Reinholz et al.
CANCER RESEARCH (2016)
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
Beverly L. Falcon et al.
PHARMACOLOGY & THERAPEUTICS (2016)
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson et al.
CANCER DISCOVERY (2016)
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy
Roberto Ronca et al.
CANCER CELL (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors
Cinta Hierro et al.
SEMINARS IN ONCOLOGY (2015)
Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
Elizabeth Catherine Smyth et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
J. -C. Soria et al.
ANNALS OF ONCOLOGY (2014)
FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
Murry W. Wynes et al.
CLINICAL CANCER RESEARCH (2014)
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
Fabrice Andre et al.
CANCER RESEARCH (2013)
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2013)
Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
Hideki Terai et al.
MOLECULAR CANCER RESEARCH (2013)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
Ezia Bello et al.
CANCER RESEARCH (2011)
High-Resolution Genomic Analysis of the 11q13 Amplicon in Breast Cancers Identifies Synergy with 8p12 Amplification, Involving the mTOR Targets S6K2 and 4EBP1
Elin Karlsson et al.
GENES CHROMOSOMES & CANCER (2011)
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas Turner et al.
CANCER RESEARCH (2010)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis
S. S. Kwek et al.
ONCOGENE (2009)
Direct multiplexed measurement of gene expression with color-coded probe pairs
Gary K. Geiss et al.
NATURE BIOTECHNOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
Somaia Elbauomy Elsheikh et al.
BREAST CANCER RESEARCH (2007)
Share Paper
